Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?;L'irradiation pelvienne est-elle toujours justifiée dans le traitement des cancers de la prostate par irradiation exclusive ?

Cancer/Radiotherapie

Volumn 13, Issue 5, 2009, Pages 416-422

  Chapet, O ^a   Quero, L ^b   Azria, D ^c   Bossi, A ^d   Hennequin, C ^b   Paparel, P ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Irradiation; Nodes; Pelvis; Prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANATOMICAL VARIATION; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LYMPH NODE; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68749092852     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.11.006     Document Type: Short Survey

References (29)

1. Allaf M.E., Palapattu G.S., Trock B.J., Carter H.B., and Walsh P.C. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
2. Asbell S.O., Martz K.L., Shin K.H., Sause W.T., Doggett R.L., Perez C.A., et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40 (1998) 769-782
3. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
4. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 168 (2002) 514-518
5. Burkhard F.C., Bader P., Schneider E., Markwalder R., and Studer U.E. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol 42 (2002) 84-90
6. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
7. D'Amico A.V., Renshaw A.A., Loffredo B., and Chen M.H. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and six months of hormone therapy. Cancer 110 (2007) 1723-1728
8. Delmas V., Durand X., and Boccon-Gibod L. Anatomical basis of lymph node dissection in prostate cancer. Prog Urol 14 (2004) 252-254
9. DiMarco D.S., Zincke H., Sebo T.J., Slezak J., Bergstralh E.J., and Blute M.L. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
10. Golimbu M., Provet J., Al-Askari S., and Morales P. Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology 30 (1987) 427-435
11. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
12. Lawton C.A., DeSilvio M., Roach III M., Uhl V., Kirsch R., Seider M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
13. Nguyen P.L., and D'Amico A. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 26 (2008) 2055-2056
14. Pan C.C., Kim K.Y., Taylor J.M., McLaughlin P.W., and Sandler H.M. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 1139-1145
15. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
16. Perez C.A., Michalski J., Brown K.C., and Lockett M.A. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36 (1996) 573-584
17. Ploysongsang S.S., Aron B.S., and Shehata W.M. Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate?. Urology 40 (1992) 18-26
18. Pommier P., Chabaud S., Lagrange J.L., Richaud P., Lesaunier F., Le Prise E., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5373
19. Roach III M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
20. Roach III M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
21. Roach III M., Marquez C., Yuo H.S., Narayan P., Coleman L., Nseyo U.O., et al. Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
22. Seaward S.A., Weinberg V., Lewis P., Leigh B., Phillips T.L., and Roach III M. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 1055-1062
23. Seaward S.A., Weinberg V., Lewis P., Leigh B., Phillips T.L., and Roach III M. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 4 (1998) 370-377
24. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., and Studer U.E. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer?. Eur Urol 50 (2006) 272-279
25. Touijer K., Rabbani F., Otero J.R., Secin F.P., Eastham J.A., Scardino P.T., et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted robability of nodal metastasis greater than 1%. J Urol 178 (2007) 120-124
26. Vargas C.E., Galalae R., Demanes J., Harsolia A., Meldolesi E., Nürnberg N., et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63 (2005) 1474-1482
27. Wawroschek F., Vogt H., Weckermann D., Wagner T., Hamm M., and Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166 (2001) 1715-1719
28. Weckermann D., Dorn R., Trefz M., Wagner T., Wawroschek F., and Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 177 (2007) 916-920
29. Zagars G.K., von Eschenbach A.C., Johnson D.E., and Oswald M.J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60 (1987) 1489-1499